

# INDEX

Note: Page numbers of article titles are in **boldface** type.

- Accessory cells, in autoimmune thyroid disease, 690-694
- Albumin, abnormalities of, detection of, 594-595  
 free hormone hypothesis and, 600  
 physicochemical properties of, 586  
 variations in, 591-592
- Analbuminemia, 592
- Anaplastic thyroid carcinoma, 726  
 fine-needle aspiration in, 703  
 treatment of, 730-731
- Aspiration, fine-needle, of thyroid, 699-709  
 in cancer diagnosis, 728-729  
 ultrasonographic guidance of, 716-719
- Autoimmune thyroid disease, 683-697  
 autoreactive T cells in, 687  
 defective autoreactivity control in, 683-685  
 definition of, 685  
 Graves' disease as, 687-689  
 Hashimoto's thyroiditis as, 689-690  
 in congenital hypothyroidism, 649  
 iodine deficiency and, 692-694  
 major histocompatibility complex cells in, 690-694  
 self-tolerance and, 683-685  
 simple goiter as, 690  
 thyroid atrophy as, 690  
 thyroid autoantibodies in, 685-686
- Automation, of thyroid function testing, 631-644
- Biopsy, fine-needle aspiration, of thyroid, 699-709  
 in cancer diagnosis, 728-729  
 ultrasonographic guidance of, 716-719
- Cancer, thyroid, 725-738  
 classification of, 726-727  
 computed tomography of, 721-722  
 diagnosis of, 727-729  
 differentiated, thyroglobulin measurements in, 731-732  
 epidemiology of, 725  
 magnetic resonance imaging of, 723  
 prognosis for, 729-730  
 recurrent, monitoring for, 732-733  
 treatment of, 729-732  
 ultrasonography of, 718
- Carbohydrates, thyroid hormone action and, 552-553
- Clinical Laboratory Improvement Amendments of 1988. See under *Regulatory and legislative issues.*
- Colloid nodule, fine-needle aspiration in, 701
- Computed tomography, of thyroid gland, 719-722
- COUP-TF, thyroid hormone receptor auxiliary proteins and, 534-535  
 transcription factor reactions with, 536
- Cytology, fine-needle. See *Fine-needle aspiration.*
- Cytosolic thyroid hormone binding proteins, 537-538
- Dendritic cells, in autoimmune thyroid disease, 690-694
- Department of Health and Human Services, laboratory regulations of, 741
- Depression, transthyretin levels in, 591
- Diabetic ketoacidosis, thyroxine-binding globulin levels in, 589
- Dialysis methods, in free thyroxine measurement, 613-615, 654-656, 663-667
- DNA, thyroid hormone receptor interactions with, 533-535

- Drug effects, on transthyretin levels, 591  
thyroxine-binding globulin levels, 589
- Epilepsy, thyrotropin measurements in, 678-679
- Estrogen therapy, thyroxine-binding globulin levels in, 588
- Familial dysalbuminemic hyperthyroxinemia, 591-592
- Fine-needle aspiration, of thyroid, 699-709  
in cancer diagnosis, 728-729  
ultrasonographic guidance of, 716-719
- Follicular thyroid carcinoma, 726, 730
- Follicular thyroid neoplasia, fine-needle aspiration in, 701-702
- Food and Drug Administration, laboratory regulations of, 741
- Free thyroxine. See under *Thyroxine*.
- Gene expression, thyroid hormone receptors in, 535-536
- Gene transcription, thyroid hormone receptors in, 536
- Goiter, in thyroid hormone resistance, 566-567  
intrathoracic, computed tomography of, 720  
magnetic resonance imaging of, 723  
simple, 690
- Graves' disease, autoantibodies in, 687-689  
ophthalmopathy in, computed tomography of, 721  
ultrasonography of, 718
- Hashimoto's thyroiditis, autoantibodies in, 689-690  
fine-needle aspiration in, 701
- Health Care Financing Administration, laboratory regulations of, 740-741
- High-dose hook effect, in thyrotropin assay, 676-677
- Hormones, thyroid. See *Thyroid hormones*.
- Human immunodeficiency virus infection, thyroxine-binding globulin levels in, 589
- Hürthle cell cancer, 726
- Hürthle cell neoplasms, fine-needle aspiration in, 702
- Hyperthyroidism, free thyroxine levels in, 658-660
- thyrotropin measurements in, 679-681  
thyroxine-binding globulin levels in, 588
- Hypoalbuminemia, 591-592
- Hypothyroidism, congenital, 645-652  
biochemical features of, 650  
clinical features of, 649  
epidemiology of, 648  
etiology of, 648-649  
prognosis for, 650-651  
screening methodology for, 646-648  
treatment of, 650  
free thyroxine levels in, 658-660  
thyrotropin measurements in, 679-681  
thyroxine-binding globulin levels in, 588
- Imaging, of thyroid gland. See under *Thyroid gland*.
- Immunoassay, for free thyroxine, Sephadex absorption method for, 624-625  
single-step approach to, 617-624  
analogue protein binding in, 620-622  
labeled analogue methods in, 618-620  
labeled antibody methods for, 622-624  
two-step direct approach to, 615-617  
for thyroid function testing, automation of, 631-644  
competitive, 633  
data management for, 633-634  
disadvantages of, 635  
heterogeneous, 632-633  
homogeneous, 632-633  
immunometric, 633  
performance of, 638-643  
reagent stability in, 633  
sample management in, 634  
signal detection in, 634-635  
systems for, 635-638
- Immunoglobulin G, thyrotropin-binding, 687
- Immunoradiometric assay, for thyroxine-binding globulin, 594
- Inflammation, transthyretin levels in, 591
- Interstate Quarantine Regulations, for specimen shipping, 742
- Iodine, deficiency of, major histocompatibility complex antigens and, 692-694
- Iodine radioisotopes, in thyroid imaging, 711, 713-714
- Joint Commission for Accreditation of Healthcare Organizations, requirements of, 740

- Ketoacidosis, diabetic, thyroxine-binding globulin levels in, 589
- Kety-Renkin-Crone equation, 604-605
- Kidney disorders, thyroxine-binding globulin levels in, 588
- Lipogenesis, thyroid hormones in, 553-554
- Lipolysis, thyroid hormones in, 553-554
- Liver disorders, thyroxine-binding globulin levels in, 588
- Lymphoma, fine-needle aspiration in, 702
- Magnetic resonance imaging, of thyroid, 722-723
- Major histocompatibility complex antigens, in autoimmune thyroid disease, 690-694
- Malnutrition, thyroxine-binding globulin levels in, 589  
transthyretin levels in, 591
- Medicare, regulatory aspects of, 739-740
- Medullary thyroid carcinoma, 726-727  
fine-needle aspiration in, 703  
prognosis for, 730  
treatment of, 730
- Metastatic carcinoma, thyroid, fine-needle aspiration in, 703
- Neoplasms. *See also Cancer.*  
transthyretin levels in, 591
- Newborns, hypothyroidism in, 645-652
- Nodules, thyroid. *See Thyroid gland, nodular disease of.*
- Nonthyroid sickness, free thyroxine levels in, 614-615
- Nuclear Regulatory Commission, laboratory regulations of, 741
- Occupational Safety and Health Act, laboratory regulations of, 741-742
- Ophthalmopathy, Graves', computed tomography of, 721
- Papillary thyroid carcinoma, 726  
fine-needle aspiration in, 702  
prognosis for, 729-730  
treatment of, 730
- Pentagastrin test, in thyroid cancer, 731-732
- Personnel standards, for laboratories, 745-747
- Pituitary-thyroid axis, free thyroxine-thyrotropin relationships and, 660-661  
thyrotropin production and, 674-676
- Porphyria, thyroxine-binding globulin levels in, 589
- Pregnancy, free thyroxine levels in, 611-612  
thyroxine-binding globulin levels in, 588
- Proficiency testing, requirements for, 747-749
- Proteins, for thyroid hormone transport. *See Thyroid hormones, transport proteins for.*
- Protirelin, 674
- Psychiatric disorders, thyrotropin measurements in, 678
- Public Law 100-587. *See Regulatory and legislative issues, Clinical Laboratory Improvement Amendments of 1988.*
- Quality control, regulations on, 744-745
- Radioimmunoassay, for free thyroxine, 615, 654  
for thyroxine-binding globulin, 594
- Radioisotope studies, of thyroid gland, 711-714  
in cancer, 728
- Radiotherapy, in thyroid cancer, 730
- Receptors, thyroid hormone. *See Thyroid hormone receptor(s).*
- Regulatory and legislative issues, 739-752  
Clinical Laboratory Improvement Act of 1967, 740-741  
Clinical Laboratory Improvement Amendments of 1988, advisory committee for, 750-751  
complexity model in, 744-745  
corrections to, 751  
events leading to, 742-743  
laboratory defined in, 743-744  
personnel standards in, 745-747  
proficiency testing in, 747-749  
quality control in, 749-750  
test management in, 750  
waived testing in, 744-745  
Department of Health and Human Services in, 741  
Food and Drug Administration in, 741  
history of, 739-744  
Interstate Quarantine Regulations in, 742  
Medicare as, 739-740  
Nuclear Regulatory Commission in, 741

- Regulatory and legislative issues  
(Continued)
- Occupational Safety and Health Act in, 741-742
  - Resource Conservation and Recovery Act in, 742
- Resistance, to thyroid hormones. See under Thyroid hormones.
- Resource Conservation and Recovery Act, laboratory regulations of, 742
- Retinoid X receptor, 534
- Seabright Bantam syndrome, 564
- Self-tolerance, autoimmune disease and, 683-685
- T<sub>4</sub>. See *Thyroxine*.
- T lymphocytes, in autoimmune thyroid disease, 683-685, 687
- Technetium 99m pertechnetate, in thyroid imaging, 711, 713
- Test management, regulations on, 750
- Thallium 201, in thyroid imaging, 711, 714
- Thyroglobulin, antibodies to, 685-686
  - in simple goiter, 690
  - in thyroid atrophy, 690
  - determination of, in thyroid cancer, 728, 731-732
- Thyroid function testing, automation of, 631-644
  - immunoassays for, accuracy of, 639-641
    - data management for, 633-634
    - disadvantages of, 635
    - future trends in, 643
    - lot-to-lot variation in, 641-642
    - method comparison in, 642
    - performance evaluation in, 642-643
    - precision of, 638
    - reagent stability in, 633
    - sample management for, 634
    - sensitivity of, 638-639
    - signal detection in, 634-635
    - systems for, 635-638
    - type of, 632-633
  - for congenital hypothyroidism, 645-652
  - transport protein variations effects on, 592-593
- Thyroid gland, atrophy of, 690
- autoimmune disease of, 683-697
- cancer of. See under *Cancer*.
- computed tomography of, 719-722
- diffuse disease of, ultrasonography of, 718
- fine-needle aspiration of, 699-709
  - imaging for, 716-719
  - in cancer diagnosis, 728-729
  - ultrasonographic guidance of, 716-719
  - imaging of, 711-724
    - computed tomography in, 719-722
    - for fine-needle aspiration, 716-719
    - magnetic resonance in, 722-723
    - nuclear techniques in, 711-714
    - ultrasound in, 714-719
  - magnetic resonance imaging of, 722-723
  - nodular disease of, computed tomography of, 720
    - fine-needle aspiration in, 701
    - ultrasonography of, 716, 718-719
    - versus cancer, 725
  - nuclear medicine imaging of, 711-714
  - physical examination of, 727
  - ultrasonography of, 714-719
- Thyroid growth-stimulating antibodies, in Hashimoto's thyroiditis, 689
- Thyroid hormone auxiliary proteins, 548
- Thyroid hormone receptor(s),
  - developmental functions of, 555-556
  - DNA interactions of, 533-535
  - historical review of, 543-546
  - in gene expression, 535-536
  - in transcription initiation, 536
  - molecular biology of, 546-550
  - mutation of, hormone resistance in, 571-577
  - tissue distribution of, 548-550
- Thyroid hormone receptor auxiliary proteins, 533-534
- Thyroid hormone response elements, 532-533, 535, 550-552
  - in hormone resistance, 571, 575-576
- Thyroid hormones. See also *Thyroxine*.
- determination of, transport protein variations effects on, 592-593
  - in thyroid cancer, 727-728
  - mechanism of action of, 531-541, 543-561
    - at developmental level, 555-556
    - central hypothesis for, 531-532
    - coordinate, 552-554
    - DNA interactions in, 533-535
    - gene expression in, 535-536
    - historical review of, 543-546
    - lipogenesis and lipolysis and, 553-554
    - nontranscriptional, 536-538
    - nutritional influences on, 552-553
    - receptors in. See *Thyroid hormone receptor(s)*.
    - thyroid hormone response elements in, 532-533, 535, 550-552
    - transcription initiation in, 536
  - resistance to, 563-581
    - classification of, 564-565
    - clinical features of, 566-567
    - diagnosis of, 567-571
    - etiology of, 571-575

- generalized tissue, 564  
 inheritance of, 565-566  
 pathophysiology of, 575-577  
 peripheral tissue, 565  
 pituitary, 564  
 prevalence of, 565  
 tissue changes in, 569-571  
 treatment of, 577  
 transport proteins for, 583-598  
   abnormalities of, detection of, 594-595  
   dissociation of, 603-604  
   dynamic equilibrium of, 601  
   hormone distribution and, 600  
   physicochemical properties of, 584-586  
   variations in, 586-592  
   thyroid function tests affected by, 592-593
- Thyroid-associated lymphoid tissue, in autoimmune disease, 687
- Thyroidectomy, in thyroid cancer, 730-731
- Thyroiditis, Hashimoto's, autoantibodies in, 689-690  
   fine-needle aspiration in, 701  
   subacute, fine-needle aspiration in, 701  
   ultrasonography of, 718
- Thyroid-stimulating antibodies, in Graves' disease, 687-689
- Thyroperoxidase, autoantibodies to, 686  
   in thyroid atrophy, 690  
   in thyroiditis, 689-690
- Thyrotropin, levels of, versus free thyroxine levels, 660-670  
   measurement of, 673-682  
   algorithm for, in thyroid disease, 680-681  
   analytic considerations in, 676-677  
   elevated values from, significance of, 679  
   in congenital hypothyroidism screening, 646-648  
   in epilepsy, 678-679  
   in psychiatric disorders, 678  
   in thyroxine replacement therapy, 677-678  
   in thyroxine suppressive therapy, 678  
   pituitary function and, 674-676  
   sensitivity of, 673-674  
   terminology of, 673-674  
   suppression of, monitoring in, 678
- Thyrotropin receptor, autoantibodies to, 686  
   in Graves' disease, 687-689
- Thyrotropin-binding immunoglobulin G, 687
- Thyrotropin-releasing hormone stimulating test, 674-675
- Thyroxine, determination of, in congenital hypothyroidism screening, 646-648  
   free, 599-629  
   capillary penetration by, 606-6110  
   equilibrium of, with bound state, 600-601  
   hypothesis concerning, 599-612  
     basic concepts of, 599-603  
     physicochemical basis of, 603-606  
     physicochemical effects of, 606-611  
     physiologic effects of, 611-612  
   in pregnancy, 611-612  
   measurement of, 612-625, 653-672  
     dialysis techniques for, 613-615, 654-656, 663-667  
     immunoassays in, 615-625  
     in nonthyroidal disorders, 657-658  
     in thyroidal disorders, 658-659  
     in vivo, 656-657  
     methods for, 654-656  
     normal physiology and, 653-654  
     radioimmunoassay, 615, 656  
     radioimmunoassay/dialysis in, 615  
     thyrotropin levels and, 660-670  
     ultrafiltration in, 613-615  
   replacement therapy with, in congenital hypothyroidism, 650  
   thyrotropin monitoring in, 677-678  
   suppressive therapy with, thyrotropin monitoring in, 678
- Thyroxine suppressive therapy, in thyroid cancer diagnosis, 728
- Thyroxine-binding globulin, abnormalities of, detection of, 594  
   deficiency of, 586  
   free hormone hypothesis and, 600  
   physicochemical properties of, 584-585  
   variations in, 586-589, 592-593
- TNM classification, of thyroid cancer, 726-727
- Transport proteins, for thyroid hormones. See *Thyroid hormones, transport proteins for.*
- Transthyretin, abnormalities of, detection of, 594-595  
   free hormone hypothesis and, 600  
   physicochemical properties of, 585-586  
   variations in, 589-593
- TSH. See *Thyrotropin.*
- Tumor markers, in thyroid cancer, 728
- Ultrafiltration, in free thyroxine measurement, 613-615
- Ultrasonography, of thyroid, 714-719, 728  
   for fine-needle aspiration, 716-719